Magenta Therapeutics, Inc.
MGTA · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $6 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | – | – | – |
| R&D Expenses | $83 | $55 | $47 | $51 |
| G&A Expenses | $25 | $26 | $28 | $28 |
| SG&A Expenses | $25 | $26 | $28 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $108 | $81 | $75 | $79 |
| Operating Income | -$102 | -$81 | -$75 | -$79 |
| % Margin | -1,633.7% | – | – | – |
| Other Income/Exp. Net | $17 | $4 | $4 | $4 |
| Pre-Tax Income | -$85 | -$76 | -$71 | -$75 |
| Tax Expense | $0 | -$4 | -$6 | -$6 |
| Net Income | -$85 | -$72 | -$66 | -$69 |
| % Margin | -1,362.8% | – | – | – |
| EPS | -21.75 | -23.05 | -1.12 | -1.43 |
| % Growth | 5.6% | -1,958% | 21.7% | – |
| EPS Diluted | -21.75 | -23.05 | -1.12 | -1.43 |
| Weighted Avg Shares Out | 4 | 3 | 59 | 48 |
| Weighted Avg Shares Out Dil | 4 | 3 | 59 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $0 | $4 | $4 |
| Interest Expense | $0 | -$4 | $0 | $0 |
| Depreciation & Amortization | $0 | $2 | $2 | $2 |
| EBITDA | -$102 | -$79 | -$75 | -$79 |
| % Margin | -1,633.7% | – | – | – |